Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Imaging-Based Prediction Of Molecular Therapy Targets In NSCLC By Radiogenomics And AI Approaches: A Systematic Review

G. Ninatti, M. Kirienko, E. Neri, M. Sollini, A. Chiti
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The objective of this systematic review was to analyze the current state of the art of imaging-derived biomarkers predictive of genetic alterations and immunotherapy targets in lung cancer. We included original research studies reporting the development and validation of imaging feature-based models. The overall quality, the standard of reporting and the advancements towards clinical practice were assessed. Eighteen out of the 24 selected articles were classified as “high-quality” studies according to the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). The 18 “high-quality papers” adhered to Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) with a mean of 62.9%. The majority of “high-quality” studies (16/18) were classified as phase II. The most commonly used imaging predictors were radiomic features, followed by visual qualitative computed tomography (CT) features, convolutional neural network-based approaches and positron emission tomography (PET) parameters, all used alone or combined with clinicopathologic features. The majority (14/18) were focused on the prediction of epidermal growth factor receptor (EGFR) mutation. Thirty-five imaging-based models were built to predict the EGFR status. The model’s performances ranged from weak (n = 5) to acceptable (n = 11), to excellent (n = 18) and outstanding (n = 1) in the validation set. Positive outcomes were also reported for the prediction of ALK rearrangement, ALK/ROS1/RET fusions and programmed cell death ligand 1 (PD-L1) expression. Despite the promising results in terms of predictive performance, image-based models, suffering from methodological bias, require further validation before replacing traditional molecular pathology testing.
This paper references
10.1097/JTO.0000000000000033
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Y. Shi (2014)
10.1259/bjr.20180334
Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks.
Jun-feng Xiong (2018)
10.1056/NEJMoa1408440
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
B. Solomon (2014)
10.1186/s13244-019-0764-0
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
N. deSouza (2019)
10.1038/srep41674
Predictive radiogenomics modeling of EGFR mutation status in lung cancer
O. Gevaert (2017)
10.1177/1758835918763493
PD-L1 expression testing in non-small cell lung cancer
C. Teixidó (2018)
10.1007/s13244-018-0657-7
Radiomics and liquid biopsy in oncology: the holons of systems medicine
E. Neri (2018)
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
A. Midha (2015)
10.1016/j.jtho.2019.03.022
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
J. Remon (2019)
10.1093/annonc/mdx288
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
C. Mayo-de-las-Casas (2017)
10.1097/MNM.0000000000001043
Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT.
Mengmeng Jiang (2019)
10.1200/JCO.2012.44.2806
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
L. Sequist (2013)
10.1016/j.radonc.2018.03.033
Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score.
S. Sanduleanu (2018)
10.1016/S1470-2045(17)30608-3
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Y. Wu (2017)
10.1093/annonc/mdx017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
J. Remon (2017)
10.1016/J.CLLC.2019.05.006
Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
D. Mendoza (2019)
10.1093/annonc/mdz196
Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients?
P. Hofman (2019)
10.1007/s00259-019-04592-1
Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer
J. Zhang (2019)
10.1186/s12916-018-1099-2
Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement
P. Heus (2018)
10.1056/NEJMoa0810699
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
T. Mok (2009)
10.1016/J.LUNGCAN.2019.03.025
Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology.
Wenting Tu (2019)
10.1200/JCO.2017.76.7293
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula
G. Kalemkerian (2018)
10.1200/JCO.2014.58.3302
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
J. Mazieres (2015)
10.1136/bmj.m689
Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies
M. Nagendran (2020)
10.1056/NEJMoa1713137
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
J. Soria (2018)
10.1016/S0140-6736(17)30565-2
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
T. Hida (2017)
10.3389/fonc.2019.01485
The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma
W. Zhao (2019)
10.1148/radiol.2020191145
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
A. Zwanenburg (2020)
10.1148/radiol.2019190173
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park (2019)
10.1002/cam4.2233
Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning
W. Zhao (2019)
10.1056/NEJMoa1613493
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer
D. Carbone (2017)
10.3389/fonc.2019.01062
Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
X. Li (2019)
10.1200/JCO.2011.36.8456
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
J. Han (2012)
10.1007/s00330-019-06360-z
Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement
J. Park (2019)
10.1007/s00259-019-04372-x
Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics
M. Sollini (2019)
10.1016/j.jtho.2018.07.101
The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell‐Free DNA in Advanced Lung Cancer
S. Laufer-Geva (2018)
10.1111/1759-7714.13163
Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
Xiao-xiao Wang (2019)
10.1148/rg.2017170077
Deep Learning: A Primer for Radiologists.
G. Chartrand (2017)
10.1088/1361-6560/ab6f98
A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
Xiaoqian Lu (2020)
10.1002/mp.13747
Radiomics for the Prediction of EGFR Mutation Subtypes in Non-small-cell Lung Cancer.
S. Li (2019)
10.1158/0008-5472.CAN-17-0122
Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.
E. Rios Velazquez (2017)
10.3389/fonc.2019.00129
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
J. Saarenheimo (2019)
10.7326/M14-0697
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
Gary S. Collins (2015)
10.1016/S1470-2045(15)70054-9
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
N. Rizvi (2015)
10.1038/s41598-018-36421-0
CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study
Y. Li (2018)
10.1016/j.patrec.2005.10.010
An introduction to ROC analysis
T. Fawcett (2006)
10.1016/j.ejrad.2009.01.050
Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging.
Aaron M Rutman (2009)
10.1148/radiol.2015151169
Radiomics: Images Are More than Pictures, They Are Data
R. Gillies (2016)
10.1016/S0140-6736(18)32409-7
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
T. Mok (2019)
10.1056/NEJMoa1810171
Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer
R. Camidge (2018)
10.1016/j.tranon.2017.10.012
Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer
L. Zhang (2018)
10.1148/radiol.14140789
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
S. Yamamoto (2014)
10.1056/NEJMoa1406766
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
A. Shaw (2014)
10.1038/s41379-019-0339-0
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
B. G. Skov (2019)
10.1634/theoncologist.2018-0706
Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Xinguan Yang (2019)
10.1016/S0140-6736(17)30123-X
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria (2017)
10.1093/annonc/mdu089
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
J. Vansteenkiste (2014)
10.1056/NEJMoa0909530
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
M. Maemondo (2010)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
10.1016/S1470-2045(19)30690-4
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
A. Drilon (2019)
10.18632/oncotarget.12587
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-lun Zhang (2016)
10.1016/S0140-6736(16)00004-0
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F. Barlési (2016)
10.1097/JTO.0b013e3181ec173d
Receiver operating characteristic curve in diagnostic test assessment.
J. Mandrekar (2010)
10.1056/NEJMoa1501824
Pembrolizumab for the treatment of non-small-cell lung cancer.
E. Garon (2015)
10.1200/JCO.18.02236
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
A. Shaw (2019)
10.1016/j.acra.2019.04.016
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Mengmeng Jiang (2019)
10.1093/annonc/mdt205
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden (2013)
10.1007/s00261-019-02028-w
Radiogenomics: bridging imaging and genomics
Z. Bodalal (2019)
10.1016/J.LUNGCAN.2019.06.005
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
A. Haragan (2019)
10.1111/1759-7714.13352
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon (2020)
10.1148/radiol.2017171920
Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction.
S. Park (2018)
10.1007/s12149-019-01414-0
Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT
S. Koyasu (2019)
10.1038/s41598-017-00426-y
PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology
M. Sollini (2017)
10.1093/annonc/mdx706
Are liquid biopsies a surrogate for tissue EGFR testing?
J. Goldman (2018)
10.1056/NEJMOA050753
Erlotinib in previously treated non-small-cell lung cancer.
F. Shepherd (2005)
10.1097/JTO.0000000000000516
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
L. Sholl (2015)
10.1080/14737140.2019.1699407
Durvalumab for the treatment of non-small cell lung cancer
S. Murakami (2019)
10.5858/arpa.2017-0388-CP
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
N. Lindeman (2018)
10.1007/s00330-019-06024-y
Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling
Tian-ying Jia (2019)
10.1016/j.media.2017.07.005
A survey on deep learning in medical image analysis
G. Litjens (2017)
10.18632/oncotarget.24893
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis
Robin W Jansen (2018)
10.1097/MD.0000000000001753
Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
Hyun Jung Yoon (2015)
10.1016/j.ejrad.2018.11.032
Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
S. Rizzo (2019)
10.1183/13993003.00986-2018
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
S. Wang (2019)
10.1007/s00259-019-04531-0
Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018
M. Sollini (2019)
10.1158/1078-0432.CCR-11-3265
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
S. Dogan (2012)
10.1016/j.ymeth.2020.01.007
PET/CT radiomics in breast cancer: mind the step.
M. Sollini (2020)
10.1016/j.jtho.2018.05.030
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
C. Rolfo (2018)
10.21037/jtd.2018.11.03
Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks.
X. Li (2018)
10.1016/j.remnie.2019.11.002
Interdisciplinarity: An essential requirement for translation of radiomics research into clinical practice -a systematic review focused on thoracic oncology.
M. Sollini (2020)
10.1016/S0140-6736(19)30037-6
Reporting of artificial intelligence prediction models
G. Collins (2019)
10.1158/1535-7163.MCT-14-0983
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
S. Patel (2015)
10.1056/NEJMoa1716948
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
M. Socinski (2018)
10.1097/JTO.0000000000000625
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
O. Gautschi (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar